Usefulness of change to anagliptin from other DPP-4 inhibitors in patients with uncontroled LDL-cholesterol
Phase of Trial: Phase IV
Latest Information Update: 18 May 2016
Price : $35 *
At a glance
- Drugs Anagliptin (Primary)
- Indications Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 19 Nov 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 20 May 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 04 Dec 2013 New trial record